This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Inflectra® (infliximab) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

GONCZI L, et al

A prospective, nationwide, multicentre, observational study to examine the efficacy, safety and immunogenicity of Inflectra/CT-P13* (infliximab) in the induction treatment of CD and UC.1,2

​​​​​​​Efficacy

​​​​​​​CT-P13* was effective in inducing and maintaining remission in both CD and UC.1,2

Clinical response/remission2

Final results: 1 year follow-up in 229 patients

Created from Gonczi, et al. 2017.

Mean CRP1

Created from Gonczi L, et al. 2017.
CRP reductions were maintained throughout 54 weeks.2

Primary endpoint1

  •  Early clinical remission at 14 weeks

Secondary endpoints1

  • Early clinical and biochemical response, immunogeicity and safety at 14 weeks
  • ​​​​​​​Clinical response, remission and steroid-free remission at week 30
  • No new safety signals were detected during this study.
​​​​​​​

Explore more

Crohn’s disease safety

Learn about the safety profile of Inflectra in patients with Crohn’s disease

Learn more

Crohn’s disease dosing

Learn about the dosing and administration of Inflectra in patients with Crohn’s disease

Find out more

*CT-P13 is marketed under different brand names including Inflectra and REMSIMA®.
CD=Crohn's disease; UC=Ulcerative colitis; CRP=C-reactive protein.
References
  1. Gecse KB, et al. J Crohns Colitis 2016. 10(2):133-40.
  2. Gonczi L, et al. Inflamm Bowel Dis 2017. 23(11):1908-15.
PP-IFA-GBR-0413. March 2021

Quick Links

  • GONCZI L et al

  • Study 3.4

  • NOR-SWITCH safety

  • NOR-SWITCH efficacy

  • PROSIT-BIO safety

  • PROSIT-BIO efficacy

  • PROSIT-BIO study design

  • Switch studies

  • Paediatric studies

  • Induction & Maintenance

  • Inflammatory bowel disease

Learn about the mechanism of action of Infliximab.

The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

Find out more

** This is an optional area where footnotes can live.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No